CDA | Evidence Driven
CDA | Evidence Driven

Treanda for Chronic Lymphocytic Leukemia (Relapsed/ Refractory)

Details

Files
Generic Name:
Bendamustine hydrochloride
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia (relapsed/refractory)
Manufacturer:
Lundbeck Canada Inc.
Brand Name:
Treanda
Project Line:
Reimbursement Review
Project Number:
PC0011-000
Performance Metric:
N/A — Predated performance metrics
Strength:
25mg/vial and 100mg/vial
Tumour Type:
Leukemia
Indications:
Chronic lymphocytic leukemia (Relapsed/ Refractory)
Funding Request:
Patients with Chronic Lymphocytic Leukemia (relapsed/refractory) for whom fludarabine-based therapy is not appropriate
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Lundbeck Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Clarification:
As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL was deferred to the January 17, 2013 pERC meeting date, once the submitter provided the requested additional economic information. Please see the Bendamustine (Treanda) for Chronic Lymphocytic Leukemia (First Line) Details page for more information.
pERC Meeting:
Final Recommendation Issued:

As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL was deferred to the January 17, 2013 pERC meeting date, once the submitter provided the requested additional economic information. Please see the Bendamustine (Treanda) for Chronic Lymphocytic Leukemia (First Line) Details page for more information.

Files

Provincial Funding Summary View PDF
Bendamustine (Treanda) CLL (Relapsed/Refractory) - pERC Final Recommendation Final Recommendation November 29, 2012 View PDF
Bendamustine (Treanda) for CLL (Relapsed/Refractory)- Final Clinical Guidance Report Guidance Reports November 29, 2012 View PDF
Bendamustine (Treanda) for CLL (Relapsed/Refractory) - Final Economic Guidance Report Guidance Reports November 29, 2012 View PDF
Bendamustine (Treanda) for CLL - pERC Initial Recommendation Initial Recommendation October 4, 2012 View PDF
Bendamustine (Treanda) for CLL (Relapsed/Refractory) - PAG Feedback on Initial Recommendation Feedback November 29, 2012 View PDF
Bendamustine (Treanda) for CLL (Relapsed/Refractory) - Manufacturer (Lundbeck Canada) Feedback on Initial Recommendation Feedback November 29, 2012 View PDF
Bendamustine (Treanda) for CLL (Relapsed/Refractory) - Patient Advocacy Group (CLL PAG) Feedback on Initial Recommendation Feedback November 29, 2012 View PDF
Bendamustine (Treanda) for CLL (Relapsed/Refractory) - Patient Advocacy Group (CLL PAG) COI Declarations Feedback November 29, 2012 View PDF
Bendamustine (Treanda) for CLL (Relapsed/Refractory) - Patient Advocacy Group (LLSC) COI Declarations Feedback November 29, 2012 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : December 14, 2012